Clinical trial
Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
Name
EFC13738
Description
Primary Objective:
Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to \<18 years old).
Secondary Objective:
Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to \<18 years old).
Trial arms
Trial start
2018-04-11
Estimated PCD
2025-11-20
Trial end
2025-11-20
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Eliglustat GZ385660
Pharmaceutical form: Capsule, Liquid
Route of administration: Oral
Arms:
Cohort 1: Eliglustat monotherapy, Cohort 2: Eliglustat plus imiglucerase
Other names:
Cerdelga
Imiglucerase GZ437843
Pharmaceutical form: Powder for solution for infusion
Route of administration: Intravenous
Arms:
Cohort 2: Eliglustat plus imiglucerase
Other names:
Cerezyme
Size
57
Primary endpoint
Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax
Weeks 2, 13, 26 and 52
Assessment of PK parameter of eliglustat: AUC
Weeks 2 and 52
Adverse Events
Up to Week 364
Eligibility criteria
Inclusion criteria :
* The patient is 2 to \<18 years old at the time of informed consent.
* Male and female patients with a clinical diagnosis of Gaucher disease (GD) type 1 or type 3 with documented deficiency of acid beta-glucosidase activity by enzyme assay and glucocerebrosidase (GBA) genotype.
* Postmenarchal female patients must have a documented negative pregnancy test prior to enrollment and throughout the study. Patients must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use a medically accepted form of contraception throughout the study.
Cohort 1 (Eliglustat monotherapy):
* Patients must have been receiving an enzyme replacement therapy (ERT) for a minimum of 24 months at a monthly dose equivalent to 30 U/kg to 130 U/kg of Cerezyme® (imiglucerase) with treatment ongoing at the time of enrollment. Patients must be at pre-specified treatment goals, as defined by:
* Hemoglobin level for ages 2 to \<12 years: ≥11.0 g/dL; for ages 12 to \<18 years: ≥11.0 g/dL for females and ≥12.0 g/dL for males;
* Platelet count ≥100,000/mm3;
* Spleen volume \<10.0 multiples of normal (MN);
* Liver volume \<1.5 MN;
* Absence of GD related pulmonary disease, and severe bone disease, as defined below for Cohort 2.
Cohort 2 (Eliglustat plus imiglucerase):
* Patients must have been receiving an ERT for a minimum of 36 months at a dose equivalent to at least 60 U/kg of imiglucerase every 2 weeks, or at the maximum dose locally approved, at the time of enrollment with treatment ongoing at the time of enrollment and the dose stable for at least the 6 months preceding enrollment. Patients must have severe clinical manifestations of GD, as defined by the presence of at least one of the following:
* GD related pulmonary disease such as interstitial lung disease (ILD). The diagnosis of ILD must be confirmed by the presence of reticulonodular densities on chest X-ray; AND/OR
* Symptomatic bone disease characterized by pathological fracture, osteonecrosis, osteopenia/osteoporosis, or bone crisis occurring in the 12 months prior to enrollment; AND/OR
* Persistent thrombocytopenia (\<80,000/mm3) related to GD.
Exclusion criteria:
* Substrate reduction therapy for GD within 6 months prior to enrollment.
* Partial or total splenectomy if performed within 2 years prior to enrollment
* The patient is transfusion dependent, a history of esophageal varices or liver infarction, elevated liver enzymes, significant congenital cardiac defect, coronary artery disease or left sided heart failure; clinically significant arrhythmias or conduction defect such as Type 2 second degree or third degree atrioventricular (AV) block, complete bundle branch block, prolonged QTc interval, or sustained ventricular tachycardia (VT).
* The patient has any clinically significant disease other than GD.
* The patient has neurological symptoms other than oculomotor apraxia at study entry.
* The patient has received an investigational product within 30 days prior to enrollment.
* The patient is unable to receive treatment with imiglucerase due to a known hypersensitivity or is unwilling to receive imiglucerase treatment every 2 weeks.
* The patient has a known hereditary galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption, or is a CYP2D6 ultra-rapid metabolizer or indeterminate metabolizer.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 57, 'type': 'ACTUAL'}}
Updated at
2024-02-20
1 organization
2 products
2 indications
Product
EliglustatIndication
Gaucher's Disease Type IIndication
Gaucher's Disease Type IIIOrganization
SanofiProduct
Imiglucerase